Clinical interventions for diagnosed aging diseases that bridge traditional care with longevity innovation.
Towards the end of last year, we unveiled the Ten Levels of Longevity framework, a detailed and structured guide designed to navigate the growing field of longevity science. Following on from our discussion of Level 4, longevity clinical services, it is now time to build upon foundational levels, as we delve into Level 5: aging disease management
Level 5: aging disease management
Clinical interventions that manage the symptoms of diagnosed aging diseases (i.e. current mainstream healthcare).
Aging disease management encompasses clinical interventions aimed at managing the symptoms of diagnosed aging-related diseases. This level represents the intersection of mainstream healthcare and longevity science, focusing on treating conditions that become more prevalent with age, such as cardiovascular diseases, diabetes, and neurodegenerative disorders.
Traditionally, healthcare systems have operated within a “sickcare” paradigm, addressing diseases as they arise. However, the longevity sector is shifting towards a more proactive approach, emphasizing the prevention and management of aging-related diseases before they manifest. This transition involves integrating advanced diagnostics, personalized medicine, and innovative therapeutic strategies to enhance patient outcomes and quality of life.
Investment opportunities in aging disease management
The aging global population presents significant investment opportunities in the healthcare sector. As the proportion of older adults increases, so does the demand for effective disease management solutions. Investors are keenly interested in companies developing therapies that target the underlying mechanisms of aging, aiming to prevent or mitigate age-related diseases.
Emerging technologies, such as artificial intelligence (AI) and machine learning, are being leveraged to identify novel drug candidates and optimize treatment protocols. AI-driven platforms can analyze vast datasets to uncover patterns and predict disease progression, facilitating the development of personalized treatment plans.
Additionally, companies focusing on regenerative medicine, including stem cell therapies and gene editing, are attracting investment for their potential to repair or replace damaged tissues and organs, offering hope for conditions previously deemed untreatable.
Companies active at Level 5
Several companies are at the forefront of aging disease management, developing innovative therapies and interventions:
Cyclarity Therapeutics
Biotechnology firm Cyclarity is developing drugs targeting age-related diseases by using cyclodextrin molecules designed to bind and remove harmful substances from the body. Their approach aims to prevent or slow the progression of conditions such as atherosclerosis, heart disease and stroke.
BioAge Labs
Focused on developing novel therapies for obesity and metabolic diseases, BioAge Labs employs a proprietary platform to identify molecular mediators of aging and disease. While the company recently halted its phase 2 trial evaluating azelaprag for obesity, it continues to focus on its broader pipeline. The company’s CNS-penetrant NLRP3 is a key mediator of chronic inflammation that develops with age, and BioAge’s inhibitor program is targeting neuroinflammation and its links to metabolic and neurodegenerative diseases, and advancing toward an IND submission in the second half of 2025. In addition, BioAge’s recently-announced collaboration with Novartis aims to target age-related diseases by uncovering molecular factors of healthy aging and exercise.
Life Biosciences
This biopharmaceutical company is dedicated to developing cellular rejuvenation therapies to combat aging and age-related diseases. Life Bioscience‘s pipeline includes programs focused on epigenetic reprogramming and chaperone-mediated autophagy, aiming to reverse or prevent multiple age-related conditions and potentially extend healthy lifespan.
Unity Biotechnology
Unity Biotechnology is developing drugs to target senescent cells, which contribute to various age-related diseases. Their senolytic medicines are designed to selectively eliminate these cells, potentially slowing the progression of diseases like osteoarthritis, eye diseases and pulmonary diseases.
Insilico Medicine
An AI-driven drug discovery company, Insilico Medicine uses powerful algorithms to analyze vast datasets and identify potential drug candidates targeting the root causes of aging-related diseases. Their focus includes developing therapies for age-associated diseases like ALS and Alzheimer’s.
These companies exemplify the innovative approaches being taken to manage aging-related diseases, bridging the gap between traditional healthcare and the emerging field of longevity science. Some of the companies above (Cyclarity, BioAge, Life Biosciences and Insilico) may cross over to Level 7: targeted aging disease reversal (organ specific / tissue specific / localized reversal), and in addition, Life Biosciences may also cross over to Level 6: aging disease prevention therapeutics.
Check out our look at Levels 1 (lifestyle management), 2 (consumer diagnostics), 3 (longevity supplements) and 4 (longevity clinics) HERE and stay tuned for Levels 6 to 10 coming over the next few weeks!
